Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

A. Xiong, N. Yang,X. Dong, Y. Fan, L. Xu,P. Pan,Y. Yu, J. Zhou, Y. Li,J. Cui, M. Wang, Y. Zhang, R. Chen, H. Niu, H. Qin, S. Guo,D. Huang, H. Wu,W. Yao, Z. Zhang, J. Fang, Y. Fang, M. Li, L. Liu,W. Su, Z. Wu, X. Wang, H. Liu, J. Hu, X. Xiang, C. Zhou

JOURNAL OF THORACIC ONCOLOGY（2024）

引用 0|浏览2